$9.28
2.62% today
Nasdaq, Feb 28, 05:21 pm CET
ISIN
US92556V1061
Symbol
VTRS

Viatris Stock price

$9.53
-1.89 16.55% 1M
-2.16 18.48% 6M
-2.92 23.45% YTD
-3.70 27.97% 1Y
-1.48 13.44% 3Y
-9.15 48.98% 5Y
-48.36 83.54% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-1.71 15.21%
ISIN
US92556V1061
Symbol
VTRS
Sector
Industry

Key metrics

Market capitalization $11.37b
Enterprise Value $25.42b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 13.05
EV/Sales (TTM) EV/Sales 1.69
P/S ratio (TTM) P/S ratio 0.76
P/B ratio (TTM) P/B ratio 0.57
Dividend yield 5.04%
Last dividend (FY24) $0.48
Revenue growth (TTM) Revenue growth -2.55%
Revenue (TTM) Revenue $15.03b
EBIT (operating result TTM) EBIT $1.42b
Free Cash Flow (TTM) Free Cash Flow $1.95b
Cash position $1.98b
EPS (TTM) EPS $-0.74
P/E forward 43.58
P/S forward 0.91
EV/Sales forward 1.85
Short interest 2.87%
Show more

Is Viatris a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Viatris Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Viatris forecast:

1x Buy
13%
5x Hold
63%
2x Sell
25%

Analyst Opinions

8 Analysts have issued a Viatris forecast:

Buy
13%
Hold
63%
Sell
25%

Financial data from Viatris

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
15,025 15,025
3% 3%
100%
- Direct Costs 8,877 8,877
2% 2%
59%
6,149 6,149
4% 4%
41%
- Selling and Administrative Expenses 1,131 1,131
104% 104%
8%
- Research and Development Expense 801 801
2% 2%
5%
4,216 4,216
16% 16%
28%
- Depreciation and Amortization 2,791 2,791
6% 6%
19%
EBIT (Operating Income) EBIT 1,425 1,425
31% 31%
9%
Net Profit -883 -883
148% 148%
-6%

In millions USD.

Don't miss a Thing! We will send you all news about Viatris directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viatris Stock News

Neutral
GlobeNewsWire
about 17 hours ago
Tokyo, Japan and Cambridge, UK, 2 8 February 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) has entered an assignment agreement with Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Pharmaceuticals Ltd (“Idorsia”), regarding the development and commercialization of cenerimod, a clinical-stage immunology candidate for autoimmune diseases, in Japan, South Korea, and c...
Neutral
Seeking Alpha
one day ago
Viatris Inc. (NASDAQ:VTRS ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer Doretta Mistras - CFO Corinne Le Goff - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Ashwani Verma - UBS Chris Schott - JPMorgan Jason Gerberry - Bank...
Negative
Seeking Alpha
one day ago
Viatris Inc. missed estimates on sales and earnings per share. The company's 2025 guidance reveals significant challenges, including a $385 million EBITDA hit from issues at the Indore plant. We would stay out of VTRS stock.
More Viatris News

Company Profile

Viatris, Inc. engages in the commercialization and manufacturing of pharmaceutical products. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Head office United States
CEO Scott Smith
Employees 38,000
Founded 2019
Website www.viatris.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today